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Abstract
Background: Patients with acute chest pain are often referred to the emergency ward and
extensively investigated. Investigations are costly and could induce unnecessary complications,
especially with invasive diagnostics. Nevertheless, chest pain patients have high mortalities. Fast
identification of high-risk patients is crucial. Therefore several strategies have been developed
including specific symptoms, signs, laboratory measurements, and imaging.
Methods/Design: The Quick Identification of acute Chest pain Study (QICS) will investigate
whether a combined use of specific symptoms and signs, electrocardiography, routine and new
laboratory measures, adjunctive imaging including electron beam (EBT) computed tomography
(CT) and contrast multislice CT (MSCT) will have a high diagnostic yield for patients with acute
chest pain. All patients will be investigated according a standardized protocol in the Emergency
Department. Serum and plasma will be frozen for future analysis for a wide range of biomarkers at
a later time point. The primary endpoint is the safe recognition of low-risk chest pain patients
directly at presentation. Secondary endpoint is the identification of a wide range of sensitive
predictive clinical markers, chemical biomarkers and radiological markers in acute chest pain
patients. Chemical biomarkers will be compared to quantitative CT measurements of coronary
atherosclerosis as a surrogate endpoint. Chemical biomarkers will also be compared in head to
head comparison and for their additional value.
Discussion: This will be a very extensive investigation of a wide range of risk predictors in acute
chest pain patients. New reliable fast and cheap diagnostic algorithm resulting from the test results
might improve chest pain patients' prognosis, and reduce unnecessary costs and diagnostic
complications.
Background
Frequently new onset chest pain is a sign of myocardial
ischemia or even (threatening) myocardial infarction.
Despite continuous improvements in diagnostic tools it
can still be difficult to differentiate between a benign and
a potential hazardous nature of acute chest pain. Percent-
ages as high as 5% of chest pain patients presenting in the
emergency room suffer or will suffer from myocardial inf-
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arction without being recognized as having an acute coro-
nary syndrome (ACS) at presentation [1]. The
consequences can be disastrous, especially when these
patients would not be admitted for rhythm surveillance. A
component of failure to recognize threatening myocardial
ischemia seems to be that discriminating non typical from
typical chest pain does not differentiate well enough
between threatening myocardial ischemia or not [1,2].
Several studies have evaluated the diagnostic accuracy of a
standard diagnostic flow chart to identify patients with
myocardial ischemia and showed good results. Therefore,
diagnostic testing at presentation or during initial hospital
admittance seems warranted. Shoyeb and colleagues con-
firmed that patients who had diagnostic tests during ini-
tial hospital admittance had better prognosis [3]. This is
why a quick but diagnostic evaluation of new onset acute
chest pain patients is needed.
New radiological techniques
One of the introduced diagnostic techniques developed is
electron beam computed tomography (EBT) scan investi-
gating the presence of coronary calcium. EBT scanning
and evaluating takes less than 20 minutes [4], and has a
low radiation load [5]. The technique doesn't require con-
trast. In review and expert opinion [4], a negative test on
coronary calcium is considered to make the presence of
vulnerable plaques or obstructive coronary artery disease
very unlikely. A positive test quantifies coronary athero-
sclerosis. It seems very clear that EBT investigations nega-
tive for calcium detection, practically rule out any risk ofa
coronary event in the next years [4]. On the other hand,
high scores are related to a high cardiac risk, and occlusive
coronary disease [6]. Although calcium scores do not have
an additional risk stratifying value in high risk patients
[7], it can have a great discriminating value in intermedi-
ate risk patients [8]. One of the recent large EBT-calcium
score studies, the St. Francis Heart Study [9], strikingly
identified high risk patients (relative risk 9.2). It was iden-
tified in patients with a calcium score >100 (a volume
score). With this it was 5 times more discriminative than
CRP.
Another type of CT scanning in coronary artery disease
(CAD) has evolved over the last decade. Multi slice CT
(MSCT) using contrast has made a true revolution in non
invasive coronary imaging, resulting in near optimal cor-
onary stenosis detection in recent studies in experienced
hands and under optimal conditions [10]. 16-slice Multi
detector CT (MDCT) coronary angiography was already
promising for detection of significant coronary artery dis-
ease in hospital admitted patients [11]. With the use of
64-slice MDCT in to the hospital admitted patients the
accuracy for detecting and ruling out significant coronary
artery disease improved further, and non calcified plaques
could be evaluated as well [12]. Modern 64-slice MDCT
has an improved resolution. Spatial resolution has
improved from 1.0 × 1.0 × 0.75 millimetres voxels to 0.4
× 0.4 × 0.4 millimetres voxels at an improved temporal
resolution of 188 milliseconds. This results in such a
detailed and non motion artefact sub millimetre visualisa-
tion of the coronary arteries that 72% of the CT coronary
angiography has exact the same result as a conventional
coronary angiography. Furthermore, amount of non-
assessable segments is seriously reduced [13]. Although
probably rare, a recent study using a 64-slice MDCT
showed negative calcium scores in patients who did have
ACS [14]. CTA with a 64-slice MDCT might be a better
investigation for ruling out ACS [15]. It is also more cost
effective than standard care as usual for low risk chest pain
patients with nuclear testing.
Accurate detection of (significant) coronary stenoses
could predict short-term cardiac risk. Correct identifica-
tion of the nature of atherosclerotic plaques, especially
cholesterol rich, dissected or thrombotic plaques could be
direct proof of ACS in chest pain patients[16]. Because of
these favourable developments in EBT and MSCT investi-
gations, we think that EBT and MSCT are promising for
future use in evaluation of CAD in outpatient stable chest
pain patients. Surprisingly, EBT (and MSCT) have rarely
been evaluated for analysis of new onset acute chest pain
patients presenting at the emergency department. To our
knowledge EBT has been evaluated limited and only for
short term outcome in the emergency department
[17,18]. Furthermore, in these studies calcium score was
not always performed directly at presentation. Longer fol-
low up is only evaluated in one other study with a series
of 192 patients presenting with chest pain in the emer-
gency department [19]. A negative calcium score on EBT
ruled out the chance of cardiac events during 50 months
follow up, and the calcium score lowered the risk ratios of
traditional risk factors. 64-slice MDCT is merely tested for
new onset acute chest pain patients presenting at the
emergency ward [12,14]. 64-slice MDCT ruled out ACS
when no plaques or stenosis could be detected. This fur-
ther indicates that CT evaluation could be discriminating
between acute chest pain patients with moderate to good
prognosis, and patients with threatening or present car-
diac events. Small studies in acute chest pain patients
proved this [12,14]. MSCT angiography has not been
tested on a large scale and is potentially harmful because
radiation and contrast exposure. Therefore, we will exe-
cute a stepwise approach. In patients with intermediate
risk first a coronary calcium score with EBT will be per-
formed. In case of an Agatston score > 10, a MSCT coro-
nary angiography will be performed. Unfortunately EBT
technology has gradually been replaced by MSCT technol-
ogy, which despite a high correlation still shows consider-
able variation especially in the lower range [20]. In our
flowchart, in case of non cardiac cause of chest pain,BMC Cardiovascular Disorders 2009, 9:24 http://www.biomedcentral.com/1471-2261/9/24
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MSCT will only be performed to rule out aortic dissection
and pulmonary embolism a clinical suspicion. This will
not be a main objective of our protocol. MSCT has already
been shown successful to triple rule out all of the poten-
tially life threatening main chest pain causes, namely aor-
tic dissection, pulmonary artery embolism and acute
coronary syndrome in small studies [21,22]. In addition
calcium scoring may overlook unstable plaques without
calcification. In our protocol the patients' presentation
therefore strongly guided the direction within the flow-
chart. In patients with a low probability, CT angiography
will be performed to rule out significant CAD only in case
of a high calcium score.
Biochemical markers
There is accumulating evidence that basal inflammatory
activity represents atherosclerotic disease [23]. Therefore
biomarkers reflecting inflammatory activity might repre-
sent the amount of systemic and the amount of coronary
atherosclerosis at the same time. It has been suggested that
inflammatory biomarkers are related to the amount of
systemic and coronary atherosclerosis. We will further
investigate the relationship with the calcium score. On the
other hand biomarkers might have additional value on
top of the calcium score. Biomarkers may reflect the unsta-
ble nature of atherosclerosis, or may induce instability
itself. Adhesion molecules are necessary for plaque infil-
tration by inflammatory cells. Oxidative stress is an
important intraplaque stimulator of inflammation. Rup-
tured plaques cause platelet adhesion and activation
which may therefore add to the diagnostic strategy in ACS.
Myocardial ischemia is the result of ACS. A problem
might be that the ECG in the acute stadium and stress test-
ing in a later stadium may not be diagnostic. Because
ischemia should be detected as early as possible because
of possible lethal complications, ischemic biomarkers
could be very important for diagnostic purposes. Testing
of biomarkers becomes more easy, cheaper and faster, and
multimarker testing in ACS has already proven prognostic
value [24]. On the other hand it has to be established for
each individual biomarker that is extensively expressed in
the coronary unstable plaque during ACS, whether its
release into the systemic circulation is high enough for
detection.
Table 1 shows biomarkers that have been tested ACS, in
short their mechanism of action in coronary syndromes,
and their observed significance in prognosis. The ideal
marker or combination of markers should safely rule out
ACS early after onset of chest pain.
Profile of biomarkers and radiological markers
Biomarkers in acute chest pain patients could be related
to: 1) inflammation, 2) oxidative stress; 3) fibrous cap
degradation; 4) coagulation or trombocyte aggregation;
5) ischemia. The experience and opinions of which is the
best biomarker reflecting one of the mentioned compo-
nents in coronary syndromes is continuously changing.
After inclusion of about 500 patients, we will test the
biomarkers that will be considered the most reliable
marker for a wide range of the mentioned components.
We will use biomarkers that can be measured after defrost-
ing, and are proven to be reliable and quickly measurable.
Because opinions and measurement techniques are con-
stantly changing, we are awaiting future developments
before deciding which biomarkers are of interest [25].
We hypothesize that in acute chest pain patients a combi-
nation of biomarkers evaluating the above mentioned
components in ACS would accurately predict the existence
of advanced systemic and coronary atherosclerosis, the
presence of an ACS, and the prognosis of the patients in
the QICS at least one-year follow-up will be assessed by
visits at the out-patient clinic and by consultation of the
municipal population registry. Extreme high biomarkers
values due to acute non-cardiac inflammation should be
excluded. We will test individual biomarkers and a profile
of biomarkers head tot head against outcome, calcium
score, presentational symptoms and traditional risk fac-
tors. We will also test individual biomarkers and profiles
of biomarkers on top of calcium score, presentational
symptoms and traditional risk factors.
Study objectives
The primary objective is to evaluate whether a negative
calcium score and/or a favourable biomarker profile can
rule out the chance of a cardiac event in the following
years. We hypothesize that EBT/MSCT and/or a biochem-
ical profile can accurately rule out cardiac chest pain fast,
(i.e. myocardial ischemia) and diagnose patients who will
survive without myocardial infarctions in the following
year. By ruling out myocardial ischemia it would prevent
unnecessary hospital admittance and invasive or extensive
ischemia testing, with all its costs and potential complica-
tions. Secondary objective is the identification of sensitive
predictive markers in acute chest pain patients. We will
test, presentational symptoms, traditional risk factors,
individual biomarkers, a profile of biomarkers, coronary
calcium score, coronary stenosis/plaque volume. Biomar-
kers will be retrospectively tested after defrosting of deep
frozen blood taken on presentation.
Methods/Design
All patients presenting with new onset acute chest pain in
the emergency department will enter the flowchart as
shown in figure 1. The flow chart has primarily been set-
up to investigate cardiac causes of chest pain and to triage
patients who need or need not undergo a cardiac catheter-
isation. Patients in whom a non-cardiac cause is suspectedB
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Table 1: shows an overview of different biomarkers that have been tested in ACS, organized by major pathophysiologic mechanism.
Main mechanism Biomarker (ref) Population tested Risk prediction
Inflammation CRP [27,28] asymptomatic subjects n = 1492
ACS population of Frisc trial
RR = 1.79 for CRP > 3.0 mg/L
RR = 3.40 for CRP > 10.0 mg/L
IL6 [29,30] ACS patients n = 43
ACS patients of Frisc II trial n = 3269
OR = 7 for in-hosptial events
RR = 3.47 (12 month mortality) for the non-invasive 
group RR = 1.43 for the invasive group
Asymptomatic:RR 1.31 ACS > RR 3.5
IL1 [29] ACS patients n = 43 OR = 11 for in hospital events
MCP1 [31] ACS n = 2270 (OPUS-TIMI16) control n = 227 HR = 1.53 for death or non-fatal MI after 10 months
IL18 [32] n = 1229 stable/instable patients
CAG reffered
HR = 3.3 for cardiovascular death in the highest vs. the 
lowest quartile
IL 10 [33] ACS n = 547 CAPTURE study HR = 0.38 for death or non-fatal MI after 6 months
SAA [34] ACS n = 435 RR = 9.7 for 14 day mortality 
(quintile 5 vs quintiles 1–4)
CRP [24,28] ACS n = 965
ACS n = 985 FRISC trial
RR = 1.35 for death or non fatal MI after 6 months
RR = 2.6 for cardiac death after 2 years
Fibrinogen [24] ACS n = 985 FRISC trial RR = 1.99 for cardiac death after 2 years
ICAM
[35-38]
elective coronary angiography n = 1246
ACS n = 91 vs control n = 24
ACS n = 114
higher in cardiovascular death, not an independent 
predictor
VCAM
[35-38]
elective coronary angiography n = 1246 ACS n = 91, 
vs control n = 24
ACS n = 114
RR = 2.8 for cardiovascular events after 2.7 years
Higher levels up till 6 months after ACS.
Levels higher in patients with MACE
OR = 4.3 for MACE 
(highest vs. lowest quartile)
sE-selectine [35-38] elective coronary angiography n = 1246
ACS n = 91 vs control n = 24
ACS n = 114
higher in cardiovascular death, not an independent 
predictor
PlGF [39] UAP
n = 544
OR = 3.3 for death median FU 4 yearsB
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Oxidative stress MPO [40,41] chest pain n = 604 ACS n = 1090 4th quartile OR = 4.1 for MACE at 6 months
HR = 2.11 for death/MI at 6 months
sPLA2 [42] ACS n = 446 HR = 3.08 for death/MI
Lp(a) [43] CAG patients n = 504 RR = 2.47 for the presence of obstructive CAD
Fibrous cap degradation MMP2 [44] ACS n = 33, SAP n = 17, control n = 17 serial elevation 2× normal value in ACS during 1 week
MMP 9 [44] ACS n = 33, SAP n = 17, control n = 17 serial elevation 2× normal value in ACS during 1 week
PAPP-A [45,46] ACS n = 37 SAP n = 19
control n = 13
ACS n = 547
Chest pain n = 644
Higher levels in ACS versus SAP/control
OR = 2.44 for 30 day death/MI
OR = 2.32 for 30 day death/MI
Coagulation or trombocyt aggregation vWF [9,47,48] STEMI n = 153
STEMI n = 86
314 STEMI
vWF release higher in cardiovascular death
vWF release OR 6.1 for 14 day composite 
endpointOR = 2.0 for 30 day maortality/MI 
(highest quartile vs quartiles 1–3)
[49] ACS 544
chest pain patients n = 626
OR = 2.71 for death/MI at 6 months
OR = 6.65
Ischemia IMA [50] ACS n = 256) negative predictive value = 96%
FFA [51] scheduled PCI n = 22 Correct prediction of ECG/troponin findings post 
procedure
Choline [52] suspected ACS n = 327 HR = 6.05 for cardiac death/non-fatal arrest in 
troponin negative group
GP-BB [53,54] chest pain n = 48
chest pain n = 107
Better prediction than CK-MB
NT-proBNP [55,56] ACS n = 1791 FRISC I
ACS n = 2019 FRISC II
OR = 3.7 for death and non-fatal MI after 30 days
HR = 4.1 for mortality after 2 years in non-invasive 
group
OR = 1.55 with every standard deviation rise
CRP = (high sensitivity) C-Reactive Protein; IL6 = interleukin6; IL1 = interleukin1; MCP1= monocyte chemoattractant protein-1; IL18 = interleukin18; IL10 = interleukin10; SAA = Serum amyloid 
A; ICAM = intercellular adhesion molecule-1; VCAM = Vascular cell adhesion molecule-1; PlGF = Placental Growth Factor; MPO = myeloperoxidase; sPLA2 = Circulating secretory 
phospholipase A2 activity; Lp(a) = Lp(a) lipoprotein; MMP2 = matrix metalloproteases-2; MMP9 = matrix metalloproteases-9; PAPP-A = Pregnancy-associated plasma protein A; vWF = von 
Willebrand factor; NT-proBNP = N-terminal pro-brain natriuretic peptide; FFA = free fatty acids; IMA = Ischemia modified albumin GP-BB = Glycogen phosphorylase isoenzym BB.
ACS = acute coronary syndrome; UAP = unstable angina pectoris; SAP = stable angina pectoris. CAG = coronary artery angiogram
OR = odds ratio; RR = relative risk; HR = hazard ratio
Table 1: shows an overview of different biomarkers that have been tested in ACS, organized by major pathophysiologic mechanism. (Continued)BMC Cardiovascular Disorders 2009, 9:24 http://www.biomedcentral.com/1471-2261/9/24
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will of course be further evaluated. This is beyond the
scope of this study protocol. Also patients admitted for ST
elevation myocardial infarction will be included at the
time of coronary angiography at primary percutaneous
coronary intervention (PCI); these patients will serve as a
positive control. A complete registration of each patient
will be obtained. Baseline demographic and clinical char-
acteristics will be collected, including age, gender, heart
rate, systolic and diastolic blood pressure, weight, length,
heart sounds and lung sounds, history of coronary artery
bypass grafting (CABG), previous PCI, myocardial infarc-
tion and stroke, existence of all traditional risk factors,
nature and duration of chest pain, electrocardiographic
signs of ischemia, time of onset of symptoms and time of
hospital admission. Additional investigation of ischemia
detection in follow up will be recorded. The final diagno-
sis non cardiac chest pain, unstable angina, non ST eleva-
tion myocardial infarction, and ST elevation myocardial
infarction, with registration of troponin and creatine
kinase levels, lipid profiles, invasive diagnostic results,
short term outcome, and long term outcome will also be
recorded. For storage of frozen blood we requested ethical
approval from the local ethical committee. The ethical
committee waved ethical approval, because storage of
blood is performed as standard for future additional test-
ing, in order to evaluate future clinical important diagnos-
tic considerations.
Flow chart for chest pain patients referred to the emergency ward Figure 1
Flow chart for chest pain patients referred to the emergency ward. Na = sodium; K = potassium; Ur = ureum; KR = 
creatinin; LDH = lactatedehydrogenase, ASAT = Aspertate-aminotransferase, ALAT = Alanine-aminotransferase, CPK = Cre-
atinekinase, CPK-MB = Creatinekinase -MB subunit, Leuco= leucocytes, Diff = blood smear differentiation, Hb = haemoglobin, 
thrombo = trombocytes Cho = total cholesterol, Tgl = triglycerides, LDC = low density cholesterol, HDC = high Density cho-
lesterol, RHD = ratio of Cho/HDL, EDTA blood = ethylenediamine-tetraacetic acid blood tube.
Standard work up
• Structured history and examination
• Vital function guard
• 12 lead ECG
• Venous access
• Laboratory analysis
• Oxygen therapy
Standard laboratory analysis
• Na, K, Ur, Kr
• LDH, ASAT, ALAT
• CK, CK-MB
• Troponin
• Leuco, diff, Hb, thrombo
• Glucose, HbA1c
• Chol, TG, LDL, HDL
• INR
- 80°  Celsius
• Citrate plasma
• EDTA plasma
• Serum
• DNA
No suspicion of 
cardiac origin of chest pain
Chest pain with high ACS probability
• Typical chest pain
• Multiple risk factors
• Abnormal ECG, without ST elevation
• First negative troponin
Myocardial infarction
• MI presentation, abnormal ECG
• ST elevation
• Positive troponin
Chest pain with low ACS probability
• Atypical chest pain
• Normal ECG
• First troponin negative
Electron Beam Tomography Electron Beam Tomography
Coronary calcium 
score 10 - 400
Coronary calcium 
score < 10
Coronary calcium 
score > 400
CT angiography during admittance
Second troponin
Coronary angiography
± intervention 
Hospital admission Safe dismissal or consultation
+
-
Exercise test
-
+BMC Cardiovascular Disorders 2009, 9:24 http://www.biomedcentral.com/1471-2261/9/24
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In- and exclusion criteria
Inclusion criteria
- New onset acute chest pain without diagnostic ECG test-
ing
- If there is a diagnostic ECG for ischemia, including ST
elevation myocardial infarction, no further delay is war-
ranted and patients will be treated accordingly without CT
analysis. Registration of baseline characteristics, collec-
tion of blood to be frozen and follow up will be obtained.
Exclusion criteria are
- If there is diagnostic testing of a non cardiac cause of
chest pain, or chest pain is evidently not cardiac, patients
will be transferred to other specialists without cardiac CT
testing.
- The existence of a life-threatening disease with a life
expectancy of less than 6 months.
All chest pain patients without exclusion criteria and with-
out cardiac history will undergo an EBT for coronary
artery calcium assessment. A coronary calcium score > 10
is considered positive and will be evaluated by ischemia
testing after ruling out infarction by troponin testing 6
hours after the start of chest pain. A coronary calcium
score > 400 is considered to justify MSCT testing in order
to rule out CAD. Depending on MSCT results and clinical
findings during further hospital admittance coronary ang-
iography will be performed.
The prognostic value of EBT calcium score will be evalu-
ated during follow up. In case MSCT is performed, plaque
characteristics will be evaluated and related to follow up.
Biomarkers will be tested and related to follow up as well
as to CT findings.
EBT Protocol
Scans will be performed with an e-Speed EBT scanner (e-
Speed, Imatron, San Francisco, CA, USA), in the dual 1.5
mm slice mode with an image acquisition time of 50 ms
or 100 ms depending on patient size. EBT data will be col-
lected during end-inspiratory breath hold. The non-
enhanced scan will be ECG-triggered at 42% of the R-R
interval. A set of 40 continuous axial coupes will be
obtained starting directly under the trachea bifurcation
until under the heart. Calcification will be defined as four
adjacent pixels with density >130 Hounsfield units. Coro-
nary artery calcification score will be calculated according
to the method of Agatston using dedicated software.
Multislice MDCT Protocol
All patients are imaged with a 64-slice MDCT scanner
(Siemens) after premeditation with oral beta-blocker and/
or intravenous metoprolol when needed. Thoracic CT
angiography with retrospective gating will subsequently
be performed with a single biphasic injection of 130 mL
of iso-osmolar contrast material (100 mL at 5 mL/sec and
30 mL at 3 mL/sec) in caudal-to-cranial acquisition. Cor-
onary, aortic, and pulmonary arterial attenuation values
will be obtained. Coronary venous and right atrial
enhancement will be evaluated to assess whether there is
interference with coronary artery evaluation.
Dual Source Computed Tomography: Procedure and 
Analysis
A retrospectively ECG-triggered DSCT scan (Somatom
Definition, Siemens Medical Systems, Forchheim, Ger-
many) with contrast enhancement will be made with a
beam current of 340 mAs/rot, tube voltage of 120 kV, and
a rotation time of 0.33 s for both tubes. ECG pulsing win-
dow will be 20–70% of the RR-interval for all patients.
Scans will be made with a slice thickness of 3.0 mm with
a 64 × 0.6 collimation. Scan direction will be was cranio-
caudal starting above the coronary ostia and ending at the
diaphragm below all cardiac structures. For the contrast
enhanced scans 73 ml of non-ionic contrast agent (Iome-
prol 400 mg I/ml, Iomeron® 400, Bracco, Italy) will be
injected in an antecubital vein. Bolus triggering will be
used for timing with the region of interest set in the
descending aorta. A 50 ml saline bolus will follow the
contrast bolus to maintain a compact bolus and to reduce
the necessary amount of contrast. All patients will be
treated with sublingual nitroglycerin (0.4 mg) just prior to
the scan protocol.
Multi-phase reconstructions will be made to select the
phase with least motion artefacts to obtain motion-free
images of the coronary arteries. In this phase of the RR-
interval final reconstructions will be made for evaluation.
Images will be reconstructed using a B26f kernel, 0.6 slice
thickness and 0.4 mm increment. 16 segments of the cor-
onary artery will be evaluated according to the model of
the American heart Association. All evaluable segments
will be classified as normal (smooth borders), as having
non-significant disease (luminal irregularities resulting in
diameter narrowing < 50%), or as having significant sten-
osis (luminal diameter narrowing ≥ 50%).
Study design
This is a single center prospective open trial.
Number of patients
We will perform an interim analysis using after 100 and
500 patients.
Duration of study
Patient recruitment has started in January 2006 and is
expected to be completed in July 2009. Analysis and
reporting is to be completed in November 2009.BMC Cardiovascular Disorders 2009, 9:24 http://www.biomedcentral.com/1471-2261/9/24
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Participating center
The study will take place at the University Medical Center
Groningen a referral center for primary PCI in STEMI
patients, serving an area in the North of the Netherlands
with approximately 1,2 million inhabitants.
Discussion
A multimarker strategy in the evaluation of acute chest
pain patients seems promising. [23] In addition, non-
invasive imaging in the acute setting may prove additonal
value. [26] Combination of these two approaches may
further improve diagnostic accuracy and prevent unneces-
sary catheterisations and reduce the number of misdiag-
nosed infarctions.
The present study set-up may further elucidate the value of
the proposed combination of biocemical and non-inva-
sive diagnostics.
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